Back to the Top
Dear All Members,
Do really mandatory of in vitro drug profiling with recombinant CYP450
enzymes or is there any alternative method?
If yes, will FDA give the clearance for it?
Is recombinant CYP450 enzymes play important role in future too?
Thanks and Regards,
Back to the Top
The following message was posted to: PharmPK
No, P450 reaction phenotyping is not "mandatory" - but it often forms part of the effort
to provide e.g "...information on the... metabolism... of the drug, if known." [IND 21CFR
If metabolism contributes a substantial part to the clearance of your drug then
understanding the enzymology of metabolism allows rational prediction of the drug
interaction potential (interaction with other drugs, diet, other environmental factors and
host genetics). If you can show that the majority of clearance is through excretion or
through metabolism via non-P450 pathways then you could make a strong argument that P450
reaction phenotyping would not be required (instead you would work to understand which
transporters or which non-P450 enzymes are involved).
Alternatives to the use of recombinant cytochrome P450 enzymes include:
Examining the effects of enzyme-selective chemical inhibitors or antibodies on the
microsomal metabolism of the drug.
Correlation studies using activity-phenotyped microsomal fractions from multiple donors.
Because of the difficulties in extrapolation of results obtained with recombinant enzymes
it is often helpful to combine multiple techniques.
Studies with recombinant enzymes are useful because the negative results are particularly
important - if you don't see metabolism of your compound, but see good turnover of a
positive control, then you can be reasonably confident that the enzyme will not play a
significant role in the disposition of your compound.
I hope that helps.
All the very best,
Bernard Murray, Ph.D.
Senior Research Scientist, Drug Metabolism
Gilead Sciences, Foster City CA
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Mandatory in vitro drug profiling required" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (email@example.com)